BEYOND OBESITY: CAN COMORBIDITY INDICATION EXPANSION UNLOCK PAYER ACCESS WHERE OBESITY IS RESTRICTED OR REFUSED?
Author(s)
Farah Moalla, BioE1, Imen Reguei, PharmD1, Lylia Chachoua, PharmD2, Aurélie Millier, PhD2, Aleksandra Caban, PharmD3, Mondher Toumi, MSc, PhD, MD4.
1Clever-Access, Tunis, Tunisia, 2Clever-Access, Paris, France, 3Clever-Access, Cracow, Poland, 4Aix-Marseille University, Marseille, France.
1Clever-Access, Tunis, Tunisia, 2Clever-Access, Paris, France, 3Clever-Access, Cracow, Poland, 4Aix-Marseille University, Marseille, France.
OBJECTIVES: When a GLP-1 demonstrates a new comorbidity benefit, does EMA grant a discrete indication (SmPC section 4.1, triggering HTA appraisal) or absorb it into section 5.1 of the existing “obesity and associated complications” indication? We examined how this framing determines payer access.
METHODS: A two-step review: first, regulatory evaluations from EMA, MHRA, TGA and Health Canada mapping how comorbidity benefits are recognised for marketed GLP-1s; second, HTA reports across key jurisdictions assessing their influence on reimbursement.
RESULTS: Type 2 diabetes, the GLP-1s' original weight-independent indication, is licensed and reimbursed separately. Regulatory classification followed mechanism rather than disease area: EMA incorporated weight-mediated benefits (HFpEF, sleep apnoea, cardiovascular risk) into SmPC section 5.1 as outcomes already covered by the obesity indication, whereas weight-independent outcomes (CKD, MASH) gained discrete recognition by FDA, linked to the reimbursed diabetes franchise or a separate brand, not the obesity label. Agencies also diverged: on similar cardiovascular evidence, the MHRA granted a discrete indication while EMA did not. Comorbidities already shape access: regulatory approval extends to overweight patients (BMI 27-30 kg/m²) only with a comorbidity, and reimbursement is often restricted to higher BMI plus a comorbidity, yet newly demonstrated comorbidity outcomes were generally absorbed, not recognised separately. Consequences depended on the reimbursement environment: absorption was immaterial where obesity was reimbursed but opened no new pathway in Europe where obesity was excluded. Conversely, comorbidity framing could circumvent this barrier, after repeatedly declining semaglutide for obesity, Australia's PBAC recommended subsidy in November 2025 for established cardiovascular disease with obesity, restricted to a prior cardiovascular event and BMI ≥35.
CONCLUSIONS: The section 4.1-versus-5.1 decision is a market-access determinant, not a formality. Where obesity is restricted or refused, comorbidity value reaches patients only if it compels a discrete indication; otherwise it is absorbed. Sponsors should prioritise weight-independent outcome evidence.
METHODS: A two-step review: first, regulatory evaluations from EMA, MHRA, TGA and Health Canada mapping how comorbidity benefits are recognised for marketed GLP-1s; second, HTA reports across key jurisdictions assessing their influence on reimbursement.
RESULTS: Type 2 diabetes, the GLP-1s' original weight-independent indication, is licensed and reimbursed separately. Regulatory classification followed mechanism rather than disease area: EMA incorporated weight-mediated benefits (HFpEF, sleep apnoea, cardiovascular risk) into SmPC section 5.1 as outcomes already covered by the obesity indication, whereas weight-independent outcomes (CKD, MASH) gained discrete recognition by FDA, linked to the reimbursed diabetes franchise or a separate brand, not the obesity label. Agencies also diverged: on similar cardiovascular evidence, the MHRA granted a discrete indication while EMA did not. Comorbidities already shape access: regulatory approval extends to overweight patients (BMI 27-30 kg/m²) only with a comorbidity, and reimbursement is often restricted to higher BMI plus a comorbidity, yet newly demonstrated comorbidity outcomes were generally absorbed, not recognised separately. Consequences depended on the reimbursement environment: absorption was immaterial where obesity was reimbursed but opened no new pathway in Europe where obesity was excluded. Conversely, comorbidity framing could circumvent this barrier, after repeatedly declining semaglutide for obesity, Australia's PBAC recommended subsidy in November 2025 for established cardiovascular disease with obesity, restricted to a prior cardiovascular event and BMI ≥35.
CONCLUSIONS: The section 4.1-versus-5.1 decision is a market-access determinant, not a formality. Where obesity is restricted or refused, comorbidity value reaches patients only if it compels a discrete indication; otherwise it is absorbed. Sponsors should prioritise weight-independent outcome evidence.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA81
Topic
Health Policy & Regulatory, Health Technology Assessment
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity)